Replies to post #251208 on Biotech Values

[TheFinalCD]

$VKTX conference call done- Summary

1) Safety profile similar to placebo even at high dose of 40mg
2) Expecting higher dose cohorts, no disclosure on how many in ph2
3) High placebo effect due to small N and diarrhea in placebo arm
4) Expecting placebo effect to move back…

— Pharmdca (@Pharmdca) March 26, 2024

$VKTX there’s seems to be no side effects with oral drug even at high doses

Profile like placebo

Remember- $VKTX is the only, only dual agonist and GIP agonist helping with counterbalancing GI side effects

✅✅

— Pharmdca (@Pharmdca) March 26, 2024

BTW Thanks for the reply

much appreciated

TEAMWORK makes the DREAMWORK
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173997658&txt2find=vktx

[Mufaso]

one has to wonder why an oral peptide drug for obesity would be a better option than a best-in-class oral small-molecule drug.

Because an oral peptide like VK2735 may have much better tolerability